We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Travere Therapeutics Inc | NASDAQ:TVTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.07 | 1.28% | 5.53 | 5.42 | 5.74 | 5.76 | 5.30 | 5.38 | 1,315,865 | 21:30:00 |
FORM 3
| Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 |
| |
1. Name and Address of Reporting Person * Cline Christopher R. |
2. Date of Event Requiring Statement (MM/DD/YYYY)
| 3. Issuer Name and Ticker or Trading Symbol Travere Therapeutics, Inc. [TVTX] |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Chief Financial Officer / | ||
5. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned | |||
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 28723 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Employee Stock Option (Right to Buy) | (1) | 8/10/2024 | Common Stock | 40000 | $12.51 | D | |
Employee Stock Option (Right to Buy) | (1) | 6/30/2025 | Common Stock | 15000 | $32.49 | D | |
Employee Stock Option (Right to Buy) | (1) | 5/18/2026 | Common Stock | 20000 | $16.23 | D | |
Employee Stock Option (Right to Buy) | (1) | 5/16/2027 | Common Stock | 20000 | $17.44 | D | |
Employee Stock Option (Right to Buy) | (1) | 5/9/2028 | Common Stock | 12500 | $25.25 | D | |
Employee Stock Option (Right to Buy) | (2) | 5/8/2029 | Common Stock | 10000 | $17.96 | D | |
Employee Stock Option (Right to Buy) | (3) | 1/30/2030 | Common Stock | 12500 | $15.46 | D | |
Employee Stock Option (Right to Buy) | (4) | 1/20/2031 | Common Stock | 16250 | $26.88 | D | |
Employee Stock Option (Right to Buy) | (5) | 1/30/2032 | Common Stock | 17500 | $27.50 | D | |
Employee Stock Option (Right to Buy) | (6) | 4/9/2032 | Common Stock | 5000 | $28.55 | D |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Cline Christopher R. C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, STE 300 SAN DIEGO, CA 92130 | Chief Financial Officer |
Signatures | ||
/s/ Elizabeth E. Reed, Attorney-in-Fact | 9/1/2022 | |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Travere Therapeutics Chart |
1 Month Travere Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions